	US 11,932,870 B2
	Compositions and methods for immune cell modulation in adoptive immunotherapies
Jonathan Rosen, San Diego, CA (US); Betsy Denise Rezner, San Diego, CA (US); Ian Hardy, San Diego, CA (US); and Eigen Peralta, San Diego, CA (US)
Assigned to Fate Therapeutics, Inc.
Appl. No. 16/466,265
Filed by Fate Therapeutics, Inc., San Diego, CA (US)
PCT Filed Dec. 4, 2017, PCT No. PCT/US2017/064507 § 371(c)(1), (2) Date Jun. 3, 2019, PCT Pub. No. WO2018/106595, PCT Pub. Date Jun. 14, 2018.
Claims priority of provisional application 62/430,263, filed on Dec. 5, 2016.
Prior Publication US 2020/0181573 A1, Jun. 11, 2020
Int. Cl. C12N 5/0783 (2010.01); A61K 35/17 (2015.01)

CPC C12N 5/0636 (2013.01) [A61K 35/17 (2013.01); C12N 5/0646 (2013.01); C12N 2501/999 (2013.01); C12N 2506/02 (2013.01); C12N 2506/45 (2013.01); C12N 2510/00 (2013.01)]

14 Claims

1. A method of treating a human subject in need thereof, the method comprising administering to the human subject a therapeutic composition comprising a population of modulated immune cells, wherein:

(a) the modulated immune cells are cells produced by culturing a population of immune cells in a culture medium to produce the modulated population of immune cells, wherein

(i) the culturing comprises inhibiting BCR-ABL tyrosine kinase; and

(ii) the culturing increases the number or ratio of one or more subpopulations comprising T cells expressing one or both of CD62L and CCR7; and

(b) the therapeutic composition comprises the T cells expressing one or both of CD62L and CCR7 in a therapeutically sufficient amount for adoptive cell therapy in said human subject in need thereof.